Lisa Beth Nachtigall, M.D.
This page shows the publications co-authored by Lisa Nachtigall and Alexander Faje.
Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014 Nov; 99(11):4078-85.
Current treatment options for hyperprolactinemia. Expert Opin Pharmacother. 2013 Aug; 14(12):1611-25.
Biochemical Control in Acromegaly With Multimodality Therapies: Outcomes From a Pituitary Center and Changes Over Time. J Clin Endocrinol Metab. 2020 03 01; 105(3).
Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019 Sep; 181(3):211-219.
Central diabetes insipidus: a previously unreported side effect of temozolomide. J Clin Endocrinol Metab. 2013 Oct; 98(10):3926-31.
Low Plasma Oxytocin Levels and Increased Psychopathology in Hypopituitary Men With Diabetes Insipidus. J Clin Endocrinol Metab. 2019 08 01; 104(8):3181-3191.
Accuracy of Late-Night Salivary Cortisol in Evaluating Postoperative Remission and Recurrence in Cushing's Disease. J Clin Endocrinol Metab. 2015 Oct; 100(10):3770-7.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.